Article
Li-Fraumeni syndrome: cancer risk assessment and clinical management.
Nature reviews. Clinical oncology - 1 May 2014
McBride Kate A, Ballinger Mandy L, Killick Emma, Kirk Judy, Tattersall Martin H N, Eeles Rosalind A, Thomas David M, Mitchell Gillian
Abstract excerpt
Carriers of germline mutations in the TP53 gene, encoding the cell-cycle regulator and tumour suppressor p53, have a markedly increased risk of cancer-related morbidity and mortality during both childhood and adulthood, and thus require appropriate and effective cancer risk management. However, the predisposition of such patients to multiorgan tumorigenesis presents a specific challenge for cancer risk management...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.